Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
, 106 (11), 1976-7

Will H. Pylori Stagger Under the Weight of This LOAD? A Novel but Expensive Eradication Regimen

Editorial

Will H. Pylori Stagger Under the Weight of This LOAD? A Novel but Expensive Eradication Regimen

James B Watson et al. Am J Gastroenterol.

Abstract

In the era of increasing Helicobacter pylori resistance to clarithromycin and metronidazole used in standard treatments, newer well-tolerated regimens with high eradication success rates in practice are urgently needed. In this edition of the American Journal of Gastroenterology, a clinical trial of a novel drug combination is presented, demonstrating significantly more success in comparison with a standard "triple therapy." The new regimen (referred to as LOAD) comprises three antibiotics, levofloxaxin, doxycycline, and nitazoxanide, together with omeprazole. The LOAD regimen had around a 90% eradication rate compared with only 73% with a standard "triple therapy" regimen of amoxicillin, clarithromycin, and lansoprazole. The use of this relatively expensive novel drug combination would represent an absolute increased eradication rate of 17%, with a number needed to treat to achieve one more successful eradication of 5.88. Results from this preliminary study should prompt further evaluation of LOAD in rigorously designed clinical studies.

Comment on

Similar articles

See all similar articles

Cited by 3 PubMed Central articles

LinkOut - more resources

Feedback